Clinical Trial Update: Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for GV1001 telomerase vaccine in patients with inoperable stage III non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• GV1001

Snippet

Sponsor: Kael-GemVax Co., Ltd. | Conditions: Inoperable Stage III Non-small Cell Lung Cancer | Phase 3 | Status: UNKNOWN